Anand, D. et al. 2026. Cardiometabolic Effectiveness and Safety of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus at High Cardiovascular Risk: A Prospective Observational Study. Adolescência e Saúde. (Sep. 2026), 454–458. DOI:https://doi.org/10.67440/ahj.vi.2007.